BioMimetic Class Action Lawsuit

BioMimetic (BMTI) is being sued by shareholders for allegedly making false statements about its financial prospects. Specifically it is being argued that BioMimetic misled investors about the prospects of its Augment Bone Graft being approved by the FDA. Additionally BioMimetic may not have properly reported problems in the Bone Graft's clinical trials. Our law firm is interested in speaking to BMTI shareholders who have losses and believe that they were misled by the company.

On May 10 2011, the FDA announced serious clinical concerns about the safety and cancer risks of the Augment Bone Graft. This was a shock to investors and shares of BioMimetic promptly dropped 35% to $8.66 per share after the news of the FDA report became public.

If you own any shares of BMTI and have losses call us now.

Kyros Law is investigating the allegations on behalf of BMTI shareholders, please call us if you have non-public information about these claims.

If you are a shareholder BMTI please call Attorney Bill Kyros at 1-800-934-2921 to discuss your rights.

Kyros Law is a Boston-based law firm with significant experience representing investors in shareholder class actions, shareholder derivative actions, and securities fraud class actions. For info about our law firm please our Kyros Law web site.